Product Program year 2025 Source: CMS Open Payments

Gadavist

Drug Radiology

NDC 50419-325-37

Open in the dashboard

General payments

$214,575

312 payments

Research payments

$1,345,755

58 payments

Through program year 2025, $214,575 in general payments and $1,345,755 in research payments were reported against Gadavist (Radiology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

14 rows
Year Kind Amount Payments
2025 General $912 9
2025 Research $227,824 7
2024 General $35,985 25
2024 Research $167,621 7
2023 General $44,031 54
2023 Research $204,826 7
2022 General $20,043 37
2022 Research $193,124 4
2021 General $54,479 26
2021 Research $148,679 8
2020 General $9,202 8
2020 Research $167,780 9
2019 General $49,922 153
2019 Research $235,902 16

Breakdown

Who paid General payments · program years 2019–2025
  1. Bayer HealthCare Pharmaceuticals Inc. $133,779 225 payments
  2. Bayer Healthcare LLC $80,796 87 payments
Top recipients General payments · program year 2025
  1. Arash Bedayat Diagnostic Radiology · Los Angeles, CA $123 13% · 1 payment
  2. Saurabh Jha Diagnostic Radiology · Philadelphia, PA $123 13% · 1 payment
  3. Joao Cavalcante Cardiovascular Disease · Minneapolis, MN $118 13% · 1 payment
  4. Andrew Arai Cardiovascular Disease · Bethesda, MD $118 13% · 1 payment
  5. Raymond Kwong Cardiovascular Disease · Boston, MA $118 13% · 1 payment

The top 5 of 9 recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Cardiovascular Disease Internal Medicine $566 62% · 5 practitioners
  2. Diagnostic Radiology Radiology $245 27% · 2 practitioners
  3. Body Imaging Radiology $87 10% · 1 practitioner
  4. Nuclear Radiology Radiology $14 2% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2025
  1. North Carolina $213 23% · 2 recipients
  2. California $123 13% · 1 recipient
  3. Pennsylvania $123 13% · 1 recipient
  4. Massachusetts $118 13% · 1 recipient
  5. Maryland $118 13% · 1 recipient

The top 5 of 8 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to Gadavist
Billing code Providers Services Paid by Medicare
Injection, gadobutrol, 0.1 ml A9585 3,135 20,730,418 $5,072,968

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

312 general · 58 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record